Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Mirum Pharmaceuticals, Inc.
  6. Financials
    MIRM   US6047491013

MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
25.58 USD   +5.66%
05/18Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
05/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/05MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 553511486812--
Enterprise Value (EV)1 553511330681695632
P/E ratio -5,35x-4,27x-5,76x-5,45x-7,58x140x
Yield ------
Capitalization / Revenue --25,4x11,3x5,08x2,82x
EV / Revenue --17,2x9,44x4,35x2,19x
EV / EBITDA ---1,91x-5,50x-6,81x-7,26x
Price to Book --4,06x6,11x32,7x11,3x
Nbr of stocks (in thousands) 22 56729 25030 48231 746--
Reference price (USD) 24,517,516,024,224,224,2
Announcement Date 03/12/202003/09/202103/09/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 --19,172,1160288
EBITDA1 ---173-124-102-87,0
Operating profit (EBIT)1 -54,7-104-173-149-10114,0
Operating Margin ---906%-206%-63,2%4,85%
Pre-Tax Profit (EBT)1 -52,5-103-84,0-154-10610,2
Net income1 -52,6-103-84,0-154-10910,2
Net margin ---439%-213%-68,1%3,53%
EPS2 -4,58-4,09-2,77-4,44-3,200,17
Dividend per Share ------
Announcement Date 03/12/202003/09/202103/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 5,003,1412,915,919,723,5
EBITDA1 -42,7-45,2-32,4-25,0-23,0-44,0
Operating profit (EBIT)1 -42,8-45,6-32,7-36,5-39,0-38,6
Operating Margin -856%-1 452%-254%-229%-198%-165%
Pre-Tax Profit (EBT)1 -47,157,6-36,6-38,2-40,8-40,4
Net income1 -47,157,5-36,6-37,7-40,7-39,8
Net margin -942%1 834%-284%-237%-206%-170%
EPS2 -1,551,91-1,17-1,20-1,30-1,16
Dividend per Share ------
Announcement Date 11/15/202103/09/202205/05/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 --157131117180
Leverage (Debt / EBITDA) --0,91x1,06x1,15x2,07x
Free Cash Flow1 -39,6-88,9-133-97,0-39,867,5
ROE (Net Profit / Equities) ---57,5%-195%-220%-104%
Shareholders' equity1 --14678,949,4-9,76
ROA (Net Profit / Asset) ---31,4%-56,8%-51,4%-37,7%
Assets1 --268271212-27,0
Book Value Per Share2 --3,933,960,742,14
Cash Flow per Share ------
Capex1 0,28--0,080,550,10
Capex / Sales ---0,12%0,34%0,04%
Announcement Date 03/12/202003/09/202103/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 812 070 430
Net sales (USD) 19 138 000
Number of employees 144
Sales / Employee (USD) 132 903
Free-Float 95,1%
Free-Float capitalization (USD) 771 983 431
Avg. Exchange 20 sessions (USD) 5 250 469
Average Daily Capital Traded 0,65%
EPS & Dividend